Statins, percutaneous coronary intervention and myocardial infarction

References

• Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003;42:1412-14
   PubMed Web of Science ®Google Scholar
• Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23:869-76
   PubMed Web of Science ®Google Scholar
• Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003;42:1406-11
   PubMed Web of Science ®Google Scholar
• Curzen N, Gurbel PA, Myat A, et al. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet 2013;382:633-43
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711-18
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109 23(Suppl 1):III 39-43
   Google Scholar
• Mood GR, Bavry AA, Roukoz, H, et al. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007;100:919-23
   PubMed Web of Science ®Google Scholar
• Bertrand ME, McFadden EP, Fruchart JC, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor After Transluminal Coronary Angioplasty. J Am Coll Cardiol 1997;30:863-9
   PubMed Web of Science ®Google Scholar
• Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 1999;20:58-69
   PubMed Web of Science ®Google Scholar
• Lee CH, de Feyter P, Serruys PW, et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart 2004;90:1156-61
   PubMed Web of Science ®Google Scholar
• Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease (GAIN). Circulation 2001;104:387-92
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-8
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wen X, Xie L, et al. Evidence of pre-procedural statin therapy. A meta-analysis of randomized trials. J Am Coll Cardiol 2010;56:1099-109
   PubMed Web of Science ®Google Scholar
• Li X, Yang Y, Hao Y, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J 2013;126:1755-60
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63
   PubMed Web of Science ®Google Scholar
• Nafasi L, Rahmani R, Shafiee A, . Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction? Curr Med Res Opin 2014;30:381-6
   PubMed Web of Science ®Google Scholar